Regenerative medicine in Europe: Global competition and innovation governance

Regenerative Medicine

Volumn 5, Issue 6, 2010, Pages 971-985

  Hogarth, Stuart ^a   Salter, Brian ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Europe; finance; governance; innovation; patenting; regulation

Indexed keywords

BIOTECHNOLOGY; CAPITAL; ECONOMIC ASPECT; ECONOMIC EVALUATION; EUROPE; FUNDING; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE MANPOWER; HEALTH CARE POLICY; HUMAN; INCOME; INDUSTRIAL PRODUCTION; INVESTMENT; MARKETING; MEDICAL RESEARCH; PATENT; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REGENERATIVE MEDICINE; REIMBURSEMENT; RESEARCH ETHICS; RESOURCE MANAGEMENT; REVIEW; STEM CELL TRANSPLANTATION; TRAINING;

BIOTECHNOLOGY; CAPITAL FINANCING; DRUG INDUSTRY; EUROPE; INTERNATIONALITY; JAPAN; ORGANIZATIONAL INNOVATION; PATENTS AS TOPIC; REGENERATIVE MEDICINE; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 78649368907     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.10.81     Document Type: Review

References (25)

1. Salter B, Salter C: Governing innovation in the biomedicine knowledge economy: stem cell science in the USA. Sci. Public Policy 37(2), 87-100 (2010).
2. Salter B, Harvey O: Stem cell innovation in the USA: the beneft of the minimal state. Regen. Med. 3(4), 597-610 (2008).
3. Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level. Organisation for Economic Co-Operation and Development, Paris, France (2006).
4. Cooke P: New economy innovation systems: biotechnology in Europe and the USA. Indust. Innov. 8(3), 267-289 (2001).
5. Levine A: Research policy and the mobility of US stem cell scientists. Nat. Biotechnol. 24(7), 865-866 (2006).
6. Martin P, Hawksley R, Turner A: The Commercial Development of Cell Therapy-Lessons for the Future? Nottingham University, Nottingham, UK (2009).
7. Nasto B: Chasing biotech across Europe. Nat. Biotechnol. 26, 283-288 (2008).
8. Ang S: Country-of-origin effect of VC investment in biotechnology companies. J. Commer. Biotechnol. 13, 12-19 (2006).
9. Yang W: 2009-turning the corner. Nat. Biotechnol. 28(2), 116-117 (2010).
10. Herpin T, Karuso H, Foley JE: Australian biotech companies: navigating the maze. J. Commer. Biotechnol. 11(2), 110-120 (2004).
11. Salter B: Governing stem cell science in China and India: emerging economies and the global politics of innovation. New Genet. Soc. 27(2), 145-159 (2008).
12. Farrell D, Jensen E, Kocher B: Why Americans pay more for healthcare. McKinsey Quarterly, December (2008).
13. Calfee J, DuPre E: The emerging market dynamics of targeted therapeutics. Health Affairs 25(5), 1302-1308 (2006).
14. Danzon P, Furukawa M: Prices and availability of biopharmaceuticals: an international comparison. Health Affairs 25(5), 1353-1361 (2006).
15. Biotechnology Report 2006. Marks and Clerk, London, UK (2006).
16. Bergman K, Graff G: The global stem cell patent landscape: implications for effcient technology transfer and commercial development. Nat. Biotechnol. 25(4), 419-424 (2007).
17. Gill S: European patent law developments in stem cell research. Pathology in Practice, February (2007).
18. Van Pottelsberghe, de la Potterie B, Mejer M: The London Agreement and the cost of patenting in Europe ECORE discussion paper (2008).
19. Tait N: Ministers back EU patent reform plan. Financial Times, 4th December (2009).
20. Salter B: The global politics of human embryonic stem cell science. Global Governance 13, 277-298 (2007).
21. Paarlberg R: The great stem cell race. Foreign Policy, May-June (2005).
22. Abraham J, Lewis G: Regulating Medicines in Europe: Competition, Expertise and Public Health. Routledge, London, UK (2000).
23. Hughes-Wilson W, Mackay D: European approval system for advanced therapies: good news for patients and innovators alike. Regen. Med. 2(1), 5-6 (2007).
24. Majone G: Regulating Europe. Routledge, London, UK (1996).
25. Rowley E, Martin P: Barriers to commercialisation and utilisation of regenerative medicine in the UK. Nottingham University, Nottingham, UK (2009).